Skip to content
Toggle main navigation
PURPOSE logo
PURPOSE logo
  • Home
  • Events
  • Opportunities
  • News & Publications
  • T90/R90 HEAL Pain Cohort Program
  • Mobile App
  • About
  • Exhibit
  • Affiliate Networks
    • Music4Pain (U24)
    • ENSEMBLE Network (U24)
    • Pain Research Forum (PRF)
    • ForceNET (U24)
    • NeuronS_MATTR (U24)
    • SPINEWORK Network (U24)
    Log in
    Request to Join

    News & Publications

    Do you have news or publications to share with the PURPOSE Network? Submit your news below.

    Submit Your News or Publication
    All
    Acquired Cognitive Impairment
    Acupuncture
    Addiction
    Ageing
    Alcohol Use / Alcohol Use Disorder (AUD)
    Analgesics
    Analgesics, Topical
    Anatomy
    Anesthesia, General
    Anesthesia, Intravenous regional
    Anesthesia, Local
    Anesthesia, Spinal
    Animal Models
    Anxiety
    Arthritis, Rheumatoid
    See all

    Highlighted News

    Results (25)

    AT-RvD1 liposomes effectively accumulate in spinal cord and reprogram microglia via ANGPTL4-SUCLG1-propionate axis for treating neuropathic pain

    AT-RvD1 liposomes effectively accumulate in spinal cord and reprogram microglia via ANGPTL4-SUCLG1-propionate axis for treating neuropathic pain

    Mater Today Bio. 2026 Oct 5;41:103726. doi: 10.1016/j.mtbio.2026.103726. eCollection 2026 Dec.ABSTRACTNeuropathic pain (NP) remains a major clinical challenge as current medications are ineffective in treating the underlying cause, and the clinical use of these drugs also has adverse reactions such as addiction. Therefore, specialized pro-resolving mediators (SPMs) may represent a promising therap
    October 20, 2026
    Now Available: Developing Peptide Therapeutics For Targeted Pain Management

    Now Available: Developing Peptide Therapeutics For Targeted Pain Management

    New Video Available: Developing Peptide Therapeutics For Targeted Pain ManagementWatch the full presentation now in the Media CenterIn Episode 18 of the PURPOSE Professional Series, Eric Gross, MD, PhD, presents peptide therapeutics as non-opioid strategies to control acute postsurgical pain and prevent chronic pain development. Dr. Gross highlights an intracellular TRPV1 peptide decoy derived fro
    September 19, 2026
    K2P channels as emerging therapeutic targets for pain: insights from functional studies and transcriptomic analyses

    K2P channels as emerging therapeutic targets for pain: insights from functional studies and transcriptomic analyses

    Front Pharmacol. 2026 Sep 3;17:1907761. doi: 10.3389/fphar.2026.1907761. eCollection 2026.ABSTRACTTwo-pore domain potassium (K2P) channels are major determinants of neuronal excitability through their ability to generate leak potassium currents that control resting membrane potential and action potential firing. Initially considered as passive background channels, K2P channels are now recognized a
    September 18, 2026
    Intrathecal semaglutide attenuates burn injury-induced pain in mice through a spinal GLP-1R-linked enkephalin/delta-opioid receptor pathway

    Intrathecal semaglutide attenuates burn injury-induced pain in mice through a spinal GLP-1R-linked enkephalin/delta-opioid receptor pathway

    Neuropharmacology. 2026 Aug 30:111163. doi: 10.1016/j.neuropharm.2026.111163. Online ahead of print.ABSTRACTBurn injury-induced pain (BIP) is a complex condition whose spinal mechanisms remain incompletely understood. Although spinal glucagon-like peptide-1 receptor (GLP-1R) signaling has been implicated in pain modulation, its contribution to BIP remains unclear. Using a mouse model of second-deg
    August 31, 2026
    Cyclodextrins in chronic pain: Membrane cholesterol remodeling and neuroimmune signaling

    Cyclodextrins in chronic pain: Membrane cholesterol remodeling and neuroimmune signaling

    Biomed Pharmacother. 2026 Aug 27;203:119889. doi: 10.1016/j.biopha.2026.119889. Online ahead of print.ABSTRACTBACKGROUND: Chronic pain remains challenging to treat, with current therapies offering incomplete relief and significant side effects. This narrative review examines cyclodextrins (CDs) beyond their conventional excipient role, focusing on their emerging function as membrane-active modulat
    August 28, 2026
    Now Available: Exploring Pain Episode 7 – Pain Mechanisms and Treatment

    Now Available: Exploring Pain Episode 7 – Pain Mechanisms and Treatment

    New Video Available: Pain Mechanisms and TreatmentWatch the full presentation now in the Media CenterIn Episode 7 of the Exploring Pain series, host Laura Wandner, PhD, sits down with Ted Price, PhD, Director of the Center for Advanced Pain Studies at UT Dallas, to explore how molecular neuroscience is advancing precision pain medicine. Price highlights single-cell transcriptomic and proteomic fin
    August 25, 2026
    Engineering Nanoscale Drug Delivery Systems for Pain

    Engineering Nanoscale Drug Delivery Systems for Pain

    Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2026 Jul-Aug;18(4):e70072. doi: 10.1002/wnan.70072.ABSTRACTPain is a pervasive and multifaceted condition that imposes a significant medical and economic burden worldwide. This burden is underscored by the urgent need for transformative, non-addictive opioid alternatives. Nanomedicine offers a promising avenue for addressing the many limitations associ
    August 7, 2026
    Phase 2b Trial of a Na(V)1.8 Inhibitor for Acute Pain

    Phase 2b Trial of a Na(V)1.8 Inhibitor for Acute Pain

    N Engl J Med. 2026 Jul 30;395(5):454-464. doi: 10.1056/NEJMoa2602910.ABSTRACTBACKGROUND: Nav1.8, a voltage-gated sodium channel expressed in the peripheral nervous system, has a critical role in pain signaling. Previous trials of NaV1.8 inhibitors have shown effectiveness in reducing postoperative pain.METHODS: We conducted a phase 2b, double-blind, randomized, placebo-controlled trial to evaluate
    August 6, 2026
    Kappa opioid receptors in excitatory spinal neurons gate acute pain: evidence from mouse and human

    Kappa opioid receptors in excitatory spinal neurons gate acute pain: evidence from mouse and human

    bioRxiv [Preprint]. 2026 Jul 6:2026.07.01.735618. doi: 10.64898/2026.07.01.735618.ABSTRACTThe kappa opioid receptor (KOR) has emerged as a promising, nonaddictive analgesic target, yet the neural mechanisms underlying KOR inhibition of pain are not entirely understood. Here, we provide converging evidence that KOR expressed on spinal neurons inhibits acute pain. We demonstrate that pharmacological
    July 17, 2026
    The Role of the Mitochondrial Permeability Transition Pore in Chronic Pain

    The Role of the Mitochondrial Permeability Transition Pore in Chronic Pain

    Curr Neuropharmacol. 2026 Jul 10. doi: 10.2174/011570159X487795260629095134. Online ahead of print.ABSTRACTThe mitochondrial Permeability Transition Pore (mPTP) has been implicated in cell death, energy failure, and oxidative stress. Emerging evidence suggests that mPTP may also contribute to the development and maintenance of chronic pain, although evidence remains limited and the underlying mech
    July 16, 2026
    Bergenin attenuates neuropathic pain by modulation of TRPV1/CGRP signalling and neuro-inflammatory mechanisms

    Bergenin attenuates neuropathic pain by modulation of TRPV1/CGRP signalling and neuro-inflammatory mechanisms

    Mol Biol Rep. 2026 Jun 18;53(1):937. doi: 10.1007/s11033-026-12098-x.ABSTRACTBACKGROUND AND PURPOSE: Neuropathic pain is a chronic and disabling condition characterized by persistent sensory hypersensitivity and inadequate treatment options. Neuroinflammation and TRPV1/CGRP-driven nociceptive pathways are critical contributors to its pathogenesis. Bergenin, a naturally occurring C-glucoside with e
    June 20, 2026
    N-methyl-d-aspartate receptor subunits interacting with regulators mediate neuropathic pain: from mechanisms to therapy

    N-methyl-d-aspartate receptor subunits interacting with regulators mediate neuropathic pain: from mechanisms to therapy

    Front Neuroendocrinol. 2026 Jun 18:101267. doi: 10.1016/j.yfrne.2026.101267. Online ahead of print.ABSTRACTNMDARs and their interacting proteins drive central sensitization in neuropathic pain, yet their pathological effects are critically shaped by upstream neuroendocrine regulators. This review synthesizes evidence across three dimensions: (i) glucocorticoids amplify pain via spinal glucocortico
    June 19, 2026
    Duration of clinically meaningful improvement in pain as a patient-centered endpoint in acute pain trials

    Duration of clinically meaningful improvement in pain as a patient-centered endpoint in acute pain trials

    Pain. 2026 Jun 22. doi: 10.1097/j.pain.0000000000004037. Online ahead of print.ABSTRACTCurrent US Food and Drug Administration (FDA) guidance recommends the sum of pain intensity differences (SPID) as the primary efficacy endpoint for acute pain trials, which lacks validated thresholds for clinically meaningful change and requires imputation of pain scores after rescue medication use. We introduce
    June 19, 2026
    Targeting Neuropilin-1 for Cancer Pain Treatment: A Trial With Potential for Clinical Translation

    Targeting Neuropilin-1 for Cancer Pain Treatment: A Trial With Potential for Clinical Translation

    Cancer Control. 2026 Jan-Dec;33:10732748261462543. doi: 10.1177/10732748261462543. Epub 2026 Jun 16.ABSTRACTCancer-associated pain is common, debilitating, and increasingly recognized not merely as a symptom but as an active participant in disease progression. Its etiology reflects a dynamic convergence of tumor-derived secretory factors, therapy-induced biochemical alterations, and a persistently
    June 17, 2026
    Decoding visceral pain: Molecular pathways and translational targets in gaseous signalling and pharmacology

    Decoding visceral pain: Molecular pathways and translational targets in gaseous signalling and pharmacology

    Br J Pharmacol. 2026 Jun 7. doi: 10.1111/bph.70526. Online ahead of print.ABSTRACTVisceral pain, a hallmark of many gastrointestinal (GI) disorders, remains a persistent clinical challenge due to its multifactorial pathophysiology and limited treatment options. Recent advances highlight the role of endogenous gaseous signalling molecules, hydrogen sulphide (H2S), nitric oxide (NO) and carbon monox
    June 9, 2026
    A landscape analysis of clinical trials in cancer pain management: current trends and emerging therapeutic targets

    A landscape analysis of clinical trials in cancer pain management: current trends and emerging therapeutic targets

    Front Oncol. 2026 May 19;16:1795684. doi: 10.3389/fonc.2026.1795684. eCollection 2026.ABSTRACTBACKGROUND: Despite a growing volume of clinical research, cancer pain management remains dependent on opioid-centric paradigms with few therapeutic breakthroughs. To identify innovation gaps and guide future research, a systematic evaluation of the global clinical trial landscape is imperative.METHODS: W
    June 4, 2026
    Recent advances in nanomaterial-based strategies for chronic pain alleviation

    Recent advances in nanomaterial-based strategies for chronic pain alleviation

    Mater Today Bio. 2026 May 23;38:103279. doi: 10.1016/j.mtbio.2026.103279. eCollection 2026 Jun.ABSTRACTChronic pain profoundly impacts global quality of life, positioning effective pain management as a critical medical priority. Currently, clinical pain treatment relies heavily on non-steroidal anti-inflammatory drugs and opioids, which, however, can lead to adverse effects and tolerance. Recent a
    June 4, 2026
    Synovial macrophage-targeted hierarchical microspheres achieve cartilage preservation and pain relief in osteoarthritis

    Synovial macrophage-targeted hierarchical microspheres achieve cartilage preservation and pain relief in osteoarthritis

    Mater Today Bio. 2026 May 22;38:103178. doi: 10.1016/j.mtbio.2026.103178. eCollection 2026 Jun.ABSTRACTPain, the hallmark symptom of osteoarthritis (OA), drives most patients to seek medical care. The current analgesics only provide partial pain relief, while fail to modify disease progression and introduce adverse effects with long-term use. Therefore, elucidating the underlying causes of OA-rela
    June 4, 2026
    Effective ropivacaine delivery using lipid nanoparticles enables simultaneous cancer therapy and pain control

    Effective ropivacaine delivery using lipid nanoparticles enables simultaneous cancer therapy and pain control

    Int J Pharm. 2026 May 30:127040. doi: 10.1016/j.ijpharm.2026.127040. Online ahead of print.ABSTRACTCancer and its associated pain pose a serious threat to human health. Cancer therapy and pain management are two distinct medical disciplines and recently proposed cancer neuroscience offers a possibility to simultaneous cancer therapy and pain control. Ropivacaine (Rop), a representative local anest
    June 1, 2026
    Discovery of MK-5661, a Once-Daily Oral Na(V)1.8 Inhibitor for the Treatment of Pain

    Discovery of MK-5661, a Once-Daily Oral Na(V)1.8 Inhibitor for the Treatment of Pain

    ACS Med Chem Lett. 2026 Apr 24;17(5):1189-1194. doi: 10.1021/acsmedchemlett.6c00132. eCollection 2026 May 14.ABSTRACTNaV1.8 is a key mediator of peripheral nociceptive signaling and an attractive nonopioid target for pain therapeutics. We report the discovery of MK 5661, a potent, selective, and orally bioavailable NaV1.8 inhibitor amenable to once-daily dosing. Optimization of an initial lead, gu
    May 20, 2026
    Contact
    Neurovations Education
    [email protected]

    United States

    PURPOSE@PainResearchers.com
    707-260-0848
    Links
    • NIH HEAL Initiative
    • Research in Pain Management